May 26, 2021

Design of TCR structural variants that retain or invert the normal activation signal

ImmunoHorizons

December 23, 2020

A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
Press release

December 9, 2020

HLA-A*02:01-directed chimeric antigen receptor/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease

Cytotherapy

December 4, 2020

Re-examination of MAGE-A3 as a T-cell Therapeutic Target
Journal of Immunotherapy

November 9, 2020

A Multivariate, Quantitative Assay that Disentangles Key Kinetic Parameters of Primary Human T Cell Function In Vitro

PLOS ONE

November 4, 2020

Cancer T-cell Therapy: Building the Foundation for a Cure

F1000Research

October 6, 2020

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics

Press release

October 2, 2020

Engineered T Cells Directed at Tumors With Defined Allelic Loss

Molecular Immunology

October 1, 2020

Engineered T Cells Directed at Tumors With Defined Allelic Loss

3rd Cell Therapies and Immunotherapy Conference

August 31,  2020

A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

The Essential Protein Engineering & Cell Therapy Summit Virtual

August 5, 2020

Structure-function Relationships of Chimeric Antigen Receptors in Acute T Cell Responses to Antigen

Molecular Immunology

November 21, 2019

Single Variable Domains from the T Cell Receptor β Chain Function as Mono-and Bifunctional CARs and TCRs

Scientific Reports

November 5, 2019

A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics

Press release